MedTrace Logo

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

NCT02443545 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2024-01-10

Study results available
· View outcomes & findings →

Summary

This is a long-term follow-up to an earlier study, LA38-0411. Its purpose is to gather more information about the safety and efficacy of deferiprone in patients with sickle cell disease or other anemias who suffer from iron overload caused by regular blood transfusions.

Conditions

Interventions

DRUG

Deferiprone

Sponsors & Collaborators

  • ApoPharma

    lead INDUSTRY

Principal Investigators

  • Janet Kwiatkowski, MD · Children's Hospital of Philadelphia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-21
Primary Completion
2019-04-30
Completion
2019-08-21

Countries

  • United States
  • Canada
  • Egypt
  • Saudi Arabia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02443545 on ClinicalTrials.gov